Landfar Bio-medicine Co., Ltd completed the acquisition of additional 29% stake in Hunan Nanhua Amspring Biotechnology Co., Ltd. from Wang Yang, Luo Yi and Changsha Aishi Pulin Information Consulting Co., Ltd. for CNY 9.7 million.
December 09, 2022
Share
Landfar Bio-medicine Co., Ltd (SZSE:000504) agreed to acquire additional 29% stake in Hunan Nanhua Amspring Biotechnology Co., Ltd. from Wang Yang, Luo Yi and Changsha Aishi Pulin Information Consulting Co., Ltd. for CNY 9.7 million on October 28, 2022.
Landfar Bio-medicine Co., Ltd (SZSE:000504) completed the acquisition of additional 29% stake in Hunan Nanhua Amspring Biotechnology Co., Ltd. from Wang Yang, Luo Yi and Changsha Aishi Pulin Information Consulting Co., Ltd. on December 10, 2022.
Landfar Bio medicine Co Ltd is a China-based company mainly engaged in the biomedical and energy conservation & environmental protection business. The Companyâs biomedical business includes stem cell storage and technical services, stem cell treatment research, medical instrument purchasing & sales. The Companyâs energy conservation & environmental protection business includes energy management company (EMC) contract energy management, build-transfer (BT), product sales, and sewage treatment. The Company is involved in other businesses related to aid and build project. The Company mainly conducts businesses within the domestic market.
Landfar Bio-medicine Co., Ltd completed the acquisition of additional 29% stake in Hunan Nanhua Amspring Biotechnology Co., Ltd. from Wang Yang, Luo Yi and Changsha Aishi Pulin Information Consulting Co., Ltd. for CNY 9.7 million.
LANDFAR BIO-MEDICINE CO., LTD 
